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Abstract
Background: Health research is increasingly being conducted on a global scale, particularly in the
developing world to address leading causes of morbidity and mortality. While research interest has
increased, building scientific capacity in the developing world has not kept pace. This often leads to
the export of human tissue (defined broadly) from the developing to the developed world for
analysis. These practices raise a number of important ethical issues that require attention.
Discussion: In the developed world, there is great heterogeneity of regulatory practices regarding
human tissues. In this paper, we outline the salient ethical issues raised by tissue exportation,
review the current ethical guidelines and norms, review the literature on what is known empirically
about perceptions and practices with respect to tissue exportation from the developing to the
developed world, set out what needs to be known in terms of a research agenda, and outline what
needs to be done immediately in terms of setting best practices. We argue that the current status
of tissue exportation is ambiguous and requires clarification lest problems that have plagued the
developed world occur in the context of global heath research with attendant worsening of
inequities. Central to solutions to current ethical concerns entail moving beyond concern with
individual level consent and embracing a robust interaction with communities engaged in research.
Conclusion: Greater attention to community engagement is required to understand the diverse
issues associated with tissue exportation.
Background
Human tissues consist of a heterogeneous set of biological
materials of interest from a scientific point of view for the
development of diagnostic and therapeutic agents, and
the study of genetic determinants of disease. Knowledge
derived from human tissues research has led to funda-
mental advances in understanding a wide range of human
diseases [1]. As clinical and basic research move to an
increasingly global scope, particularly with the recent
focus on tackling the major health issues in the develop-
ing world, it is important to understand the wide range of
ethical issues involved in the exportation of tissue from
the developing to the developed world.
Tissue analysis is a lucrative field, and it is unclear how
benefits are explained to research participants, thus ren-
dering aspects of informed consent problematic. The fate
of exported tissues is often unaccounted for, making over-
sight difficult. Guidelines are poorly adhered to, and com-
munities often not informed of the exportation, and when
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so informed, may reject such exportation and risk the loss
of potential health benefits. The following cases highlight
these unresolved ethical issues in the exportation of
human tissues for research purposes.
Three Controversial Cases Involving Tissue Exporta-
tion from the Developing to the Developed World
Case 1 Uganda
A newspaper reported that Uganda is losing millions of
dollars due to exportation of human biological samples
from the country. If this export is not stopped, researchers
say, the country might no longer attract biomedical stud-
ies, which contribute a hefty amount of foreign exchange
to the health sector. In the biomedical studies done, 80
per cent of human biological samples collected have been
exported. Reasons for exportation are stated to be lack of
storage facilities in Uganda, short supply of staff and
equipment, and limited budget to stay in Uganda. The fate
of specimens after exportation is unknown [2].
Case 2 India
Indian scientists accuse foreign researchers of violating
national guidelines, introduced in the late 1990s, which
permitted export of tissues for research only with approval
from the health ministry. The complaint is related to a
study done by molecular biologists at the University of
Cambridge analyzing DNA from saliva of 988 individuals
in Kerala, a region with the world's highest levels of natu-
ral radiation. Indian scientists question the need for
exportation of samples without approval. They fear that
India's large and diverse population might serve as a
source of valuable genetic information of potential com-
mercial value. Although guidelines are in place, there is
still no machinery to implement and regulate them [3].
Case 3 Tonga
Autogen, an Australian firm, announces an agreement
to collect tissue samples to study diabetes among Ton-
gans. Autogen promises a full range of benefits to the
community, including royalties for commercially suc-
cessful discoveries, and provision of drugs from dis-
coveries, free of charge. Tongans reject the offer, in part
because individual consent failed to capture or reflect
community values, and risked commodifying Tongan
identity [4].
In this paper, we outline the salient ethical issues raised by
tissue exportation, review the current ethical guidelines
and norms, review the literature on what is known empir-
ically about perceptions and practices with respect to tis-
sue exportation from the developing to the developed
world, set out what needs to be known in terms of a
research agenda, and outline what needs to be done
immediately in terms of setting best practices.
We argue that reliance on first person consent for tissue
exportation may be insufficient and that engagement of
communities from which tissues will be exported is a nec-
essary additional requirement. This relates as much to
establishing and evaluating proposed benchmarks for
best practices in research in the developing world and
conforming to existing guidelines, as in building trust in
terms of collaboration between north and south, and in
terms of developing truly legitimate, respectful and inclu-
sive research partnerships between the developed and
developing world. As well, a transparent and consistent
approach to tissue exportation would have non-exploita-
tion of vulnerable individuals and communities as its
goal. It would set a minimum standard of respect for these
groups to be met by all research endeavours.
Discussion
Human tissues are collected for research purposes in clin-
ical practice settings and in a variety of research contexts,
such as genetics studies of human disease, including sus-
ceptibility to infectious diseases. Currently, there is an
immense research capacity gap between developing and
developed countries. Most developing countries either
lack the sophisticated technology and laboratory infra-
structure necessary for the analysis of human tissues, or
have insufficient capacity in these technologies to permit
the analyses of large numbers of samples that is now com-
mon in high-throughput screening approaches and other
volume-intensive analysis methods. These approaches are
increasingly common in disease contexts such as HIV/
AIDS and malaria, which are major areas of research in
developing countries.
There are many compelling reasons for exporting tissues.
Exportation of tissue facilitates centralized analysis,
allows economies of scale, and creates large datasets that
can be compared and analyzed with state of the art bioin-
formatics analysis. Secondly, it concentrates expertise and
standardizes quality. There may be tangible public health
benefits resulting from this large-scale approach to science
by harnessing molecular expertise in the developed world
for application in the developing world. Therefore, there
are many reasons to believe that the efficient exportation
and centralization of the analysis of tissues can provide
benefits.
On the other hand, concerns have been raised about how
such practices could worsen health, and perhaps also eco-
nomic, disparities between the developing and developed
world [4]. Exportation fails to invest in the capacity build-
ing necessary to strengthen research in the developing
world. The analysis of tissues in the same geographical
and cultural milieu from which they have been taken may
enhance research participation. Some low and middle-
income nations are capable of developing the appropriateBMC Medical Ethics 2007, 8:11 http://www.biomedcentral.com/1472-6939/8/11
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infrastructure to perform such analysis. Cuba, Brazil and
South Africa stand as successful examples of such capacity.
As has been argued by Calestous Juma, for Africa in partic-
ular, investments in technological capacity will be an
important component of capacity building, and sustain-
ing and integrating these communities into the global
knowledge economy [5].
Major Ethical Issues
Exportation of tissues raises a host of issues concerning
the potential commodification and traffic of human iden-
tity, and the exploitation of communities from which tis-
sues have been exported. Many research projects are
taking place in the developing world in the context of
decolonialization, where concerns about continuing
domination of the developing world by former colonial
masters are still relevant.
Commodification has been defined in various ways. In
terms of tissue exportation, Dickenson views it as the
process by which tissue acquires value such that it
becomes the object of exchange. The precise value and the
entire scope of potential exchange may not be evident at
the time tissues are collected and exported. The exact
extent to which tissues collected for research purposes can
be regarded as objects of property, and who has the ulti-
mate ownership over them remains undetermined. Charo
recently drew attention to the lack of legal clarity in the
developed world over governance of human tissue, show-
ing how the dominant legal interpretations emphasize
privacy interests and autonomy in decisions to donate
human tissue for research purposes, effectively avoiding
the issue of ownership and property rights over human
tissues. The explicit recognition of such rights could have
huge implications for current research uses of human tis-
sue, possibly resulting in severe restrictions in their use
[6].
But in the same way as lack of clarity on property interests
currently favours relatively unrestricted use by researchers,
greater clarity on the relationship between donors and
their tissues may serve to enhance understanding and
ensure legitimacy.
Current practices and their legal interpretation in the
developed world, which reflect an almost exclusive reli-
ance on informed consent, raise important questions
about whether this approach provides an appropriate
model for the developing world. This is a pressing issue in
particular because of the continued advances in large-
scale bioscience endeavors involving human tissue expor-
tation. The identity value of tissues for a cultural group, as
illustrated in the Tonga scenario, may not be captured in
research processes that rely solely on agreed upon forms
of individual consent. If the identity value of tissue mat-
ters to communities that participate in research, these
interests must be given an appropriate place in determina-
tions of whether the research is ethical.
One key issue related to the use of human tissue in inter-
national collaborative research is benefit sharing. There is
potential economic benefit (as well as scientific reputa-
tion) to be derived from discoveries made from human
tissues exported from the developing world. In the devel-
oped world, controversies have arisen over patents, and
the considerable profits derived from research done on
tissues, while those contributing the tissue were unaware
of such profits and barred from sharing benefits [7].
Although legal interpretations have thus far rejected prop-
erty claims to donated tissue by the donors, these interpre-
tations do not settle the intuitive sense by many donors
that there is a meaningful relationship between them and
their tissues and that this relationship should figure some-
how in the overall calculus of benefit sharing. Given the
huge economic disparities between developed and devel-
oping world collaborators, the long history of exploita-
tion in the context of international collaborative research,
and the powerful framing effect of colonial history in
much of the developing world, simply ignoring or mar-
ginalizing questions of ownership and relationship
between donor and tissue may have higher costs to the
research enterprise than has been the case in developed
countries.
There has been an emerging perspective in the developed
world that one-time consent with future uses approved by
legitimate research ethics boards (REBs) is the best model
for managing tissue donations in research [8]. Whereas
informed first person consent for use and reuse of tissues
has become the standard in the developed world, the
model may not be adequate in the developing world con-
text. Research on tissue samples in the developing world,
specifically genetic research, is now commonly conducted
in conjunction with large-scale epidemiological research
programs. These programs go far beyond small clinical
research projects and directly implicate communities and
whole populations. Given what we know about the
potential for communities to suffer harm as a result in
their participation in research [9] and their ability to
appropriately and forcefully express their concerns about
inadequate reflection of their interests in benefit sharing
agreements [10], it seems inescapable that the prevailing
model of individual consent for the use of tissue also has
implications for communities. Many of these communi-
ties can be regarded as vulnerable and relatively disem-
powered. How communities should be engaged in
deliberations about tissue exportation, and under what
terms and conditions, remains an unanswered question.BMC Medical Ethics 2007, 8:11 http://www.biomedcentral.com/1472-6939/8/11
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Current Ethical Guidelines
Current guidelines only partially address the issues, as for
the most part guidance has been created for application in
the developed world. These documents assume that tis-
sues will be analyzed locally, and therefore are silent on
establishing criteria for legitimate exportation. Guidelines
from the developing world are similarly silent on the need
to engage communities or justify exportation. Guidelines
from both contexts universally endorse the need for
informed consent from participants, but are, for the most
part, unclear on the necessity of documenting and justify-
ing exportation, or of explaining the potential cultural sig-
nificance of tissue exportation.
Recently published ethical benchmarks for research in the
developing world establish a set of frameworks that can be
used to evaluate progress towards best practices in tissue
exportation. For example, Emanuel et al. have articulated
a set of benchmarks for research ethics in the developing
world [11]. As well as expanding concerns for the assur-
ance of the cultural appropriateness of informed consent,
there are a series of benchmarks that call for collaborative
partnerships as necessary to the ethical justification of
research in the developing world.
These benchmarks are broadly relevant to tissue exporta-
tion. They call for engagement in partnership with
national and/or international research institutions. They
recommend collaboration with local and national
researchers, health policymakers and the community.
They should share responsibilities for determining the
importance of health problems, assessing the value of the
research, and for planning, conducting, and overseeing
the research, and integrating the research into the health
system. They call for respecting the community's values,
culture, traditions and social practices. They suggest con-
tributing to capacity development for researchers and
health policy-makers, so the community can become a
full and equal partner in the research enterprise. They say
recruited participants and communities should receive
benefits from the conduct and results of research, sharing
fairly in the financial and other rewards of the research.
These benchmarks do not speak directly to determining
when tissues can and should legitimately be exported, or
of explaining the meaning and significance of exportation
as part of the process of consent. Importantly, the bench-
marks do not necessitate engagement with the commu-
nity on issues of identity that are entailed by the analysis
of tissues. These may, in fact, be the principal justification
for privileging local perspectives and values. The risk of
exploitation increases if identity concerns are not ade-
quately accounted for, as it may be harder, even impossi-
ble, to ensure truly fair distribution of benefits if such
perspectives are not known.
The common practice of stripping samples of identifiers,
which creates conditions of anonymity and renders con-
cerns for consent moot under most guidelines, is not a
constructive response to calls for increased attention to
identify issues related to the use of human tissue in
research. Once stripped of identifiers and exported from
the context where they have been collected, tissues lose
most of their scientific value, particularly in the context of
epidemiological research. The potential for meaningful
benefits that might be shared equitably is therefore dra-
matically undermined, or eliminated entirely. The protec-
tion of identity, and the recognition of a significant
relationship between donors and their tissues, even if this
has not been formally recognized by Western courts as a
formal property right, should be viewed as strong commu-
nity interests, and should be treated as such in guidelines
on these issues, and should be incorporated explicitly into
the negotiations and deliberations that establish the tissue
collection practices within any collaborative research
project.
What is Known
While there is a growing body of scholarship on the per-
spectives of research subjects regarding the use of their tis-
sues in the developed world, little is known about the
perspectives of research subjects in the developing world.
The extent to which international guidelines and pro-
posed international benchmarks are recognized, compre-
hended, or adhered to by study participants, study
communities, researchers and ethics review boards is, for
the most part, unknown. Recent empirical studies indicate
a mixed picture, with significant gaps in understanding.
A recent study in Kenya showed that a spectrum of views
exists, with a considerable complexity of perspectives con-
cerning understanding the use of tissues in research [12].
There is confusion in the eyes of many participants about
the precise distinction between the need for tissue for
research and for clinical care. More specifically, there is
confusion about what blood and tissue will be used for,
and concern about why it is necessary to export such tissue
for research purposes. Respondents reported varying
interest in being provided with the results from future
studies using their stored samples. Similar findings have
also been found in the developed world context.
Wendler et al. surveyed participants in a malaria clinical
trial in Uganda and reported that most participants were
willing to permit samples to be stored and exported, and
were willing to waive additional consent for subsequent
research, provided the study was approved by an ethics
review board [13]. Respondents also were interested in
knowing what sorts of studies stored samples would be
used in, suggesting that their expressions of willingness to
donate samples for storage and export were not exhaustiveBMC Medical Ethics 2007, 8:11 http://www.biomedcentral.com/1472-6939/8/11
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of their interests in the fate of their tissues. But the study
did not ask respondents about the deeper issues of com-
munity identity, and whether this was of concern to them
and, if so, how such concerns might be addressed in the
context of the research collaboration.
Langat, in a study of two Kenyan ethics review boards,
found that 25 per cent of protocols reviewed stated there
was a need for tissue storage and reuse, but only half actu-
ally informed participants of this. He concluded that
investigators "do not see the need to seek consent for stor-
age reuse and exportation of samples [14]."
The empirical literature points to the urgent need for fur-
ther research. If Wendler's findings are representative, the
role of REBs would be crucial in ensuring the legitimate
use of stored and exported samples. Langat's results,
though, are cautionary. Clearly if REBs are to be the locus
of approval for research on stored samples, there is a
pressing need for the creation of local REBs, and expanded
education of existing REBs on the full spectrum of ethical
issues associated with tissues research. REBs require the
capacity to monitor and audit studies to ensure not only
that appropriate informed consent has been obtained, but
that the agreed upon practices are followed by investiga-
tors. They need to ensure that communities have been
consulted. While there is currently no consensus on spe-
cific mechanisms for community consent, the practice of
eliciting broader community authorization may have a
role to play in contexts where tissues will be exported
from the community, particularly in those situations
where the analysis has implications for more than the
consenting individual.
Additionally, REB oversight on exported tissue becomes
problematic and to all intents and purposes non-existent
once the tissue has left the context from which it was
obtained. Some mechanism must be in place to account
for the fate of the tissues, and innovative ways of REB col-
laboration between North and South may be required to
aid in this oversight process.
What Needs to be Known
There is a need for more studies such as those described
above, in diverse parts of the developing world. They
should examine the extent to which tissue exportation is
consented to, and the extent to which communities that
are being researched understand the rationales for tissue
exportation and storage. There are no studies investigating
researchers' perceptions on the need for consent, or their
awareness and perspectives on guidelines. Similarly, there
have been no studies that look specifically at the perceived
relationship between donors and their tissues and the sig-
nificance of the relationship for communities. One case
study from Malawi about the use of tissue taken from the
eyes of deceased children during autopsy-based research
on causes of death from cerebral malaria [15] reveals that
tissues can have profound cultural significance, in this
case raising fears that researchers might use the tissues to
exercise supernatural powers over the deceased child and
thereby disrupt prospects for a peaceful afterlife. To avoid
previous colonial errors, such cases should not be dis-
missed as quaint by Western researchers and REBs, but
rather should encourage more and better research into the
various ways in which tissue might be imbued with rich
and powerful cultural meaning and how this meaning
might give rise to ethically significant interests on the part
of participating communities. To get at the root of these
interests it will be necessary to go beyond survey designs,
which pose questions from the perspective of the
researchers, to more naturalistic modes of enquiry, which
can help to reveal insights and meaning that survey meth-
ods can't reach [16].
There is a research agenda that should focus on broad
community engagement, including a sustained investiga-
tion of the cultural acceptability of the exportation and
storage of tissues for research purposes. It is important to
include investigators and REBs in the concept of commu-
nity engagement in the research enterprise, as the need to
harmonize expectations among all stakeholders is clearly
shown by the brief but informative empirical literature. A
series of comparative case studies looking at practices and
perceptions across several developing world contexts
would be a logical first step to informing the process.
There is also a need to address, particularly as research and
databases merge into large-scale research programs, how
best to deal with future unforeseen uses of stored exported
tissues, and to consider innovative means of engaging
research participants that can enhance local control over
data [16]. Similarly, what constitutes fair distribution of
research benefits in the context of international collabora-
tive research, and which model is best for addressing
issues of ownership or relationship between tissue donors
and their exported tissue, requires further elucidation,
including an expansion of the notion of benefits to
include the value of maintaining oversight control of val-
uable cultural property, such as genetic heritage.
Conclusion
Ensuring ethical research entails bringing communities
together in dialogue. These communities include
researchers, the researched and those who will provide
oversight, such as REBs.
At minimum, there is a need to ensure documentation of
explicit and legitimate consent for the exportation of
human tissue for research purposes. Legitimate consent
should include engagement with communities withPublish with BioMed Central    and   every 
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respect to the necessity for tissue exportation, as well as
agreed upon and explicit standards for current use, and a
process to manage future uses of exported tissue. The
length of time that such tissues will be retained, who has
access to the tissue, and all potential commercial benefits
from the tissues should be included in the documenta-
tion. Particular attention to understanding perceptions
and expectations on possible future uses of tissues is
needed. As well, models of REB accountability for
exported tissues are required and may need innovative
solutions. It is incumbent upon the investigators to
explain the reasons why capacity building locally is not
necessarily a full alternative to the need for exportation.
Provisions such as these will help build trust and ensure
transparency in communications, and will also help to
create an understanding of the cultural and social con-
cerns with tissue exportation.
However, satisfying the conditions of individual consent
is not sufficient to ensure that ethical standards have been
met. Researchers must ensure that deeper accounts of the
meaning and value of tissues as culturally meaningful arti-
facts are explicitly identified and incorporated into delib-
erations about appropriate use and exportation of tissues.
Concerns about the fair and respectful treatment of
exported tissues should also figure more prominently in
research ethics review, including developing appropriate
guidance about their fate and ultimate disposition.
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